Glaxosmithkline breathes easy as shingles treatment revives its sales – The Times

Strong sales of a new shingles vaccine have revived spirits at Glaxosmithkline and prompted it to raise its annual earnings outlook.
The London-listed drugs company yesterday announced an 11 per cent increase in third-quarter group sales to £9.4 billion, bea…

Click here to view the original article.